PT - JOURNAL ARTICLE AU - Peluso, Michael J. AU - Deveau, Tyler-Marie AU - Munter, Sadie E. AU - Ryder, Dylan AU - Buck, Amanda AU - Beck-Engeser, Gabriele AU - Chan, Fay AU - Lu, Scott AU - Goldberg, Sarah A. AU - Hoh, Rebecca AU - Tai, Viva AU - Torres, Leonel AU - Iyer, Nikita S. AU - Deswal, Monika AU - Ngo, Lynn H. AU - Buitrago, Melissa AU - Rodriguez, Antonio AU - Chen, Jessica Y. AU - Yee, Brandon C. AU - Chenna, Ahmed AU - Winslow, John W. AU - Petropoulos, Christos J. AU - Deitchman, Amelia N. AU - Hellmuth, Joanna AU - Spinelli, Matthew A. AU - Durstenfeld, Matthew S. AU - Hsue, Priscilla Y. AU - Kelly, J. Daniel AU - Martin, Jeffrey N. AU - Deeks, Steven G. AU - Hunt, Peter W. AU - Henrich, Timothy J. TI - Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID AID - 10.1101/2022.06.21.22276660 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.21.22276660 4099 - http://medrxiv.org/content/early/2022/07/22/2022.06.21.22276660.short 4100 - http://medrxiv.org/content/early/2022/07/22/2022.06.21.22276660.full AB - The presence and reactivation of chronic viral infections such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) have been proposed as potential contributors to Long COVID (LC), but studies in well-characterized post-acute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited. In a cohort of 280 adults with prior SARS-CoV-2 infection, we observed that LC symptoms such as fatigue and neurocognitive dysfunction at a median of 4 months following initial diagnosis were independently associated with serological evidence of recent EBV reactivation (early antigen-D [EA-D] IgG positivity) or high nuclear antigen IgG levels, but not with ongoing EBV viremia. Evidence of EBV reactivation (EA-D IgG) was most strongly associated with fatigue (OR 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR 0.52) and tended to have less severe (>5 symptoms reported) LC (OR 0.44). Overall, these findings suggest differential effects of chronic viral co-infections on the likelihood of developing LC and predicted distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.SUMMARY The authors found that Long COVID symptoms in a post-acute cohort were associated with serological evidence of recent EBV reactivation and pre-existing HIV infection when adjusted for participant factors, sample timing, comorbid conditions and prior hospitalization, whereas underlying CMV infection was associated with a decreased risk of Long COVID.Competing Interest StatementAC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCoSGD reports grants and/or personal fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences outside the submitted work. TJH reports consulting for Roche and Regeneron, and grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. The remaining authors report no conflicts. Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases NIH/NIAID 3R01AI141003-03S1 to TJ Henrich, R01AI158013 to M Gandhi and M Spinelli, K24AI145806 to P Hunt, and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent. The study was approved by the Institutional Review Board at the University of California, San Francisco.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.